urea has been researched along with Colitis, Granulomatous in 10 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In several cases with IgA nephropathy (IgAN), differential diagnosis is difficult due to the complication with other systemic diseases which can induce secondary IgAN." | 1.62 | Renal pathological analysis using galactose-deficient IgA1-specific monoclonal antibody is a strong tool for differentiation of primary IgA nephropathy from secondary IgA nephropathy. ( Fukao, Y; Kano, T; Kato, R; Lee, M; Makita, Y; Nakayama, M; Suzuki, H; Suzuki, Y, 2021) |
| " Information on bioavailability and release characteristics of ColoPulse tablets in Crohn's patients and the influence of food and time of food intake is a prerequisite to properly design future clinical studies with active substances in these patients." | 1.39 | ColoPulse tablets perform comparably in healthy volunteers and Crohn's patients and show no influence of food and time of food intake on bioavailability. ( Buurman, DJ; Dijkstra, G; Frijlink, HW; Kosterink, JG; Maurer, JM; Schellekens, RC; Stellaard, F; van Rieke, HM; Woerdenbag, HJ; Wutzke, KD, 2013) |
| "Children with Crohn disease have altered growth and body composition." | 1.37 | Corticosteroids increase protein breakdown and loss in newly diagnosed pediatric Crohn disease. ( Denne, SC; Noe, JD; Steiner, SJ, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (40.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, M | 1 |
| Suzuki, H | 1 |
| Kato, R | 1 |
| Fukao, Y | 1 |
| Nakayama, M | 1 |
| Kano, T | 1 |
| Makita, Y | 1 |
| Suzuki, Y | 1 |
| Maurer, JM | 1 |
| Schellekens, RC | 1 |
| van Rieke, HM | 1 |
| Stellaard, F | 1 |
| Wutzke, KD | 1 |
| Buurman, DJ | 1 |
| Dijkstra, G | 1 |
| Woerdenbag, HJ | 1 |
| Frijlink, HW | 1 |
| Kosterink, JG | 1 |
| Ando, T | 1 |
| Watanabe, O | 1 |
| Ishiguro, K | 1 |
| Maeda, O | 1 |
| Ishikawa, D | 1 |
| Minami, M | 1 |
| Hasegawa, M | 1 |
| Kondo, S | 1 |
| Goto, Y | 1 |
| Ohmiya, N | 1 |
| Niwa, Y | 1 |
| Goto, H | 1 |
| Steiner, SJ | 1 |
| Noe, JD | 1 |
| Denne, SC | 1 |
| RUBINIETZ, H | 1 |
| Kasper, H | 1 |
| Sommer, H | 1 |
| Lundsgaard, C | 2 |
| Hamberg, O | 2 |
| Thomsen, OO | 2 |
| Nielsen, OH | 2 |
| Vilstrup, H | 2 |
| Rask-Madsen, J | 1 |
| Hammersgaard, EA | 1 |
| Knudsen, E | 1 |
| Wochner, RD | 1 |
| Weissman, SM | 1 |
| Waldmann, TA | 1 |
| Houston, D | 1 |
| Berlin, NI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Peppermint Oil for the Treatment of Irritable Bowel Syndrome: Optimizing Therapeutic Strategies Using Targeted Delivery[NCT02716285] | Phase 3 | 190 participants (Actual) | Interventional | 2016-08-17 | Completed | ||
| A Randomized, Double Blind, Single Dose, Two Treatment, Two Period Crossover Pharmacokinetic Study Comparing a 182mg Colon-targeted-delivery Peppermint Oil Capsule (Tempocol-ColoPulse®) and a 182mg Enteric-coated Peppermint Oil Capsule (Tempocol®) in Heal[NCT02291445] | Phase 2 | 8 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Area under the plasma concentration-time curve from t=0 hrs until t=24 hrs. (NCT02291445)
Timeframe: 24 hours
| Intervention | ug*h/L (Median) |
|---|---|
| Ileocolonic Release PO | 2331 |
| Small Intestinal Release PO | 2623 |
Menthol-glucuronide (main constituent of peppermint oil after conversion by the liver) peak plasma concentrations (NCT02291445)
Timeframe: 24 hours
| Intervention | ug/L (Median) |
|---|---|
| Ileocolonic Release PO | 563.6 |
| Small Intestinal Release PO | 702 |
Time until a measurable plasma concentration of menthol-glucuronide occurs after oral administration of peppermint oil (45ug/L) (NCT02291445)
Timeframe: 24 hours
| Intervention | minutes (Median) |
|---|---|
| Ileocolonic Release PO | 225 |
| Small Intestinal Release PO | 37 |
Time to reach maximum menthol-glucuronide (main constituent of peppermint oil after conversion by the liver) concentration in plasma (NCT02291445)
Timeframe: 24 hours
| Intervention | minutes (Median) |
|---|---|
| Ileocolonic Release PO | 360 |
| Small Intestinal Release PO | 180 |
elimination half-life; time required for the plasma concentration of menthol-glucuronide to reach half of its original value. (NCT02291445)
Timeframe: 24 hours
| Intervention | hours (Median) |
|---|---|
| Ileocolonic Release PO | 6.1 |
| Small Intestinal Release PO | 7.7 |
1 trial available for urea and Colitis, Granulomatous
| Article | Year |
|---|---|
Increased hepatic urea synthesis in patients with active inflammatory bowel disease.
Topics: Adolescent; Adult; Aged; Amino Acids; Colitis, Ulcerative; Crohn Disease; Female; Humans; Linear Mod | 1996 |
9 other studies available for urea and Colitis, Granulomatous
| Article | Year |
|---|---|
Renal pathological analysis using galactose-deficient IgA1-specific monoclonal antibody is a strong tool for differentiation of primary IgA nephropathy from secondary IgA nephropathy.
Topics: Adult; Antibodies, Monoclonal; Antiviral Agents; Arthritis, Rheumatoid; Crohn Disease; Diagnosis, Di | 2021 |
ColoPulse tablets perform comparably in healthy volunteers and Crohn's patients and show no influence of food and time of food intake on bioavailability.
Topics: Administration, Oral; Adolescent; Adult; Biological Availability; Colon; Crohn Disease; Cross-Over S | 2013 |
ColoPulse tablets perform comparably in healthy volunteers and Crohn's patients and show no influence of food and time of food intake on bioavailability.
Topics: Administration, Oral; Adolescent; Adult; Biological Availability; Colon; Crohn Disease; Cross-Over S | 2013 |
ColoPulse tablets perform comparably in healthy volunteers and Crohn's patients and show no influence of food and time of food intake on bioavailability.
Topics: Administration, Oral; Adolescent; Adult; Biological Availability; Colon; Crohn Disease; Cross-Over S | 2013 |
ColoPulse tablets perform comparably in healthy volunteers and Crohn's patients and show no influence of food and time of food intake on bioavailability.
Topics: Administration, Oral; Adolescent; Adult; Biological Availability; Colon; Crohn Disease; Cross-Over S | 2013 |
Relationships between Helicobacter pylori infection status, endoscopic, histopathological findings, and cytokine production in the duodenum of Crohn's disease patients.
Topics: Adolescent; Adult; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Biopsy; Breath Tests; Ca | 2008 |
Corticosteroids increase protein breakdown and loss in newly diagnosed pediatric Crohn disease.
Topics: Adolescent; Blood Glucose; Body Composition; Child; Crohn Disease; Gas Chromatography-Mass Spectrome | 2011 |
[Ileitis terminalis; treatment with intestin-euvernil].
Topics: Crohn Disease; Humans; Ileitis; Urea | 1955 |
Taste thresholds in patients with Crohn's disease.
Topics: Adolescent; Adult; Aged; Crohn Disease; Female; Humans; Hydrochloric Acid; Male; Middle Aged; Nutrit | 1980 |
[Increased urea synthesis in patients with active inflammatory bowel disease].
Topics: Adult; Amino Acids; Blood Urea Nitrogen; Colitis, Ulcerative; Crohn Disease; Female; Humans; Interle | 1997 |
Rectal electrolyte transport and mucosal permeability in ulcerative colitis and Crohn's disease.
Topics: Adult; Bicarbonates; Biological Transport, Active; Chromium Isotopes; Colitis, Ulcerative; Crohn Dis | 1973 |
Direct measurement of the rates of synthesis of plasma proteins in control subjects and patients with gastrointestinal protein loss.
Topics: Amyotrophic Lateral Sclerosis; Arginine; Bicarbonates; Blood Proteins; Carbon Isotopes; Crohn Diseas | 1968 |